PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15545923-6 2004 The apical position of cathepsin B in both caspase-activation cascades was confirmed by pretreatment of the animals with the cathepsin B inhibitor CA-074, which also potently protected cortical structures from ischemic damage, indicating involvement of the proteases in the lesion process. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 147-153 cathepsin B Mus musculus 23-34 25237059-6 2014 Inflammation in B10.S mice was associated with a selective increase in activity of cysteine cathepsin B but not cathepsins L or S. Increased cathepsin B activity was not dependent on cytokines required for mHgIA but treatment with CA-074, a cathepsin B inhibitor, led to transient reduction of local induration, expression of inflammatory cytokines, and subsequent attenuation of the systemic adaptive immune response. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 231-237 cathepsin B Mus musculus 141-152 25237059-6 2014 Inflammation in B10.S mice was associated with a selective increase in activity of cysteine cathepsin B but not cathepsins L or S. Increased cathepsin B activity was not dependent on cytokines required for mHgIA but treatment with CA-074, a cathepsin B inhibitor, led to transient reduction of local induration, expression of inflammatory cytokines, and subsequent attenuation of the systemic adaptive immune response. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 231-237 cathepsin B Mus musculus 141-152 16924498-7 2007 The intracellular formation of these intermediate metabolites is at least partially dependent on the proteolytic activity of the lysosomal enzyme cathepsin B; PPX metabolism is inhibited by a highly selective inhibitor of cathepsin B, CA-074. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 235-241 cathepsin B Mus musculus 146-157 25428830-6 2015 Through our anti-osteoclastogenic compound screening experiments we encountered a modified version of the Cathepsin B inhibitor CA-074: the cell membrane-permeable CA-074Me (L-3-trans-(Propylcarbamoyl) oxirane-2-carbonyl]-L-isoleucyl-L-proline Methyl Ester). N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 128-134 cathepsin B Mus musculus 106-117 24709226-9 2014 Interestingly, BAPTA-AM and CA074 significantly decreased BPC cytotoxicity, suggesting that both calcium and cathepsin B are required for BPC antitumour activity. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 28-33 cathepsin B Mus musculus 109-120 15545923-6 2004 The apical position of cathepsin B in both caspase-activation cascades was confirmed by pretreatment of the animals with the cathepsin B inhibitor CA-074, which also potently protected cortical structures from ischemic damage, indicating involvement of the proteases in the lesion process. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 147-153 cathepsin B Mus musculus 125-136 12437121-0 2002 CA-074, but not its methyl ester CA-074Me, is a selective inhibitor of cathepsin B within living cells. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 0-6 cathepsin B Mus musculus 71-82 14612454-8 2004 Moreover, CA-074, a specific cathepsin B inhibitor, also abolished the neurotoxic effects caused by Abeta42-activated BV2 cells. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 10-16 cathepsin B Mus musculus 29-40 12437121-2 2002 The most popular substance to selectively inhibit cathepsin B in vivo is CA-074Me, the methyl ester of the E-64 derivative CA-074. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 73-79 cathepsin B Mus musculus 50-61 12437121-4 2002 In contrast, exposure of these cells to the parental compound CA-074 leads to the selective inhibition of endogenous cathepsin B, while intracellular cathepsin L remains unaffected. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 62-68 cathepsin B Mus musculus 117-128 12437121-5 2002 These results indicate that CA-074 rather than CA-074Me should be used to specifically inactivate cathepsin B within living cells. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 28-34 cathepsin B Mus musculus 98-109 10508490-3 1999 The cathepsin-B-selective E-64 derivative, CA-074, inhibited penetration of Matrigel by SCC-VII cells to the same extent, indicating a major role for this particular lysosomal enzyme in extracellular-matrix degradation during squamous-carcinoma-cell invasion. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 43-49 cathepsin B Mus musculus 4-15 10809954-1 2000 We previously reported that CA074, a specific inhibitor of cathepsin B, modulates specific immune responses from the T helper 2 (Th2) type to Th1 type in BALB/c mice infected with Leishmania major. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 28-33 cathepsin B Mus musculus 59-70 11027533-1 2000 We previously reported that CA074, a specific inhibitor of cathepsin B, significantly deviated immune responses from the disease-promoting Th2 type to the protective Th1 type in BALB/c mice infected with Leishmania major. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 28-33 cathepsin B Mus musculus 59-70 9272702-6 1997 Interestingly, CA-074, a selective inhibitor of cathepsin B, inhibited presentation of the polypeptide, indicating its involvement in the degradation of the P12-25 polypeptide. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 15-21 cathepsin B Mus musculus 48-59 35122866-3 2022 In the present study, we investigated the role of CA-074, a potent Cathepsin B inhibitor, in MS progression, using the SJL/J mouse model of experimental autoimmune encephalomyelitis (EAE). N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 50-56 cathepsin B Mus musculus 67-78 32330298-7 2020 CA-074Me is a cell permeable prodrug of CA-074, which is cell impermeable and a specific CTSB inhibitor. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 0-6 cathepsin B Mus musculus 89-93 30613015-4 2018 RESULTS: Compared with the WT mice,TLR4-/-mice receiving the lethal dose of LPS had significantly longer survival time (up to 84 h) after the injection,but were still unable to fully resist LPS challenge.CA-074 pretreatment prolonged the survival time of WT mice and TLR4-/-mice to 60 h and 132 h,respectively.In the mouse models of sepsis,20 mg/kg LPS induced significantly enhanced activity of cathepsin B without affecting its expression level in the KCs (P<0.05) and increased the serum levels of the inflammatory cytokines.CA-074 pretreatment of the mice obviously lessened the detrimental effects of LPS in TLR4-/-mice by significantly lowering cathepsin B activity in the KCs,alleviating hepatocyte apoptosis and reducing the serum levels of inflammatory cytokines. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 204-210 cathepsin B Mus musculus 396-407 30613015-4 2018 RESULTS: Compared with the WT mice,TLR4-/-mice receiving the lethal dose of LPS had significantly longer survival time (up to 84 h) after the injection,but were still unable to fully resist LPS challenge.CA-074 pretreatment prolonged the survival time of WT mice and TLR4-/-mice to 60 h and 132 h,respectively.In the mouse models of sepsis,20 mg/kg LPS induced significantly enhanced activity of cathepsin B without affecting its expression level in the KCs (P<0.05) and increased the serum levels of the inflammatory cytokines.CA-074 pretreatment of the mice obviously lessened the detrimental effects of LPS in TLR4-/-mice by significantly lowering cathepsin B activity in the KCs,alleviating hepatocyte apoptosis and reducing the serum levels of inflammatory cytokines. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 204-210 cathepsin B Mus musculus 658-669 30019185-6 2018 CTSB inhibitor (CA-074) was used to suppress the expression of CSTB. N-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-proline 16-22 cathepsin B Mus musculus 0-4